{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:28Z","timestamp":1790690788259,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019914","name":"Flatiron Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100237","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:19:39Z","timestamp":1776727179000},"page":"100237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-8953","authenticated-orcid":false,"given":"Jennifer","family":"Prescott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-0144","authenticated-orcid":false,"given":"Ahmed","family":"Sawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"De Nigris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Bloomquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxia","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Z. H.","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100237_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bneo.2026.100237_bib2","series-title":"Surveillance, Epidemiology, and End Results. Chronic Lymphocytic Leukemia - Cancer Stat Facts","year":"2025"},{"issue":"suppl 5","key":"10.1016\/j.bneo.2026.100237_bib3","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"9747","key":"10.1016\/j.bneo.2026.100237_bib4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bneo.2026.100237_bib5","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/cancers13102468","article-title":"Current treatment options in CLL","volume":"13","author":"Bewarder","year":"2021","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.bneo.2026.100237_bib6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100237_bib7","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100237_bib8","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.bneo.2026.100237_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100237_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clml.2022.09.007","article-title":"Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: a real-world database study","volume":"23","author":"Mato","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.bneo.2026.100237_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cwhat\u2019s past is prologue\u201d (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100237_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/10428194.2023.2190436","article-title":"Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study","volume":"64","author":"Eyre","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.bneo.2026.100237_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70258","article-title":"Efficacy and effectiveness outcomes of treatments for double-exposed chronic lymphocytic leukemia and small lymphocytic lymphoma patients: a systematic literature review","volume":"13","author":"Zuber","year":"2024","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100237_bib14","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1182\/blood-2023-187129","article-title":"Clinical outcomes in patients treated with both covalent Btkis and venetoclax and the significance of \u201cdouble-refractory\u201d status in patients with CLL\/SLL","volume":"142","author":"Samples","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100237_bib15","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","article-title":"Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia","volume":"9","author":"Yoon","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2026.100237_bib16","author":"Ysebaert"},{"issue":"20","key":"10.1016\/j.bneo.2026.100237_bib17","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2026.100237_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","volume":"199","author":"Hampel","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bneo.2026.100237_bib19","author":"Din"},{"key":"10.1016\/j.bneo.2026.100237_bib20","author":"Chatzikonstantinou"},{"issue":"25","key":"10.1016\/j.bneo.2026.100237_bib23","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2026.100237_bib24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0959-8049(02)00182-X","article-title":"Measuring the clinical response. What does it mean?","volume":"38","author":"Therasse","year":"2002","journal-title":"Eur J Cancer"},{"issue":"27","key":"10.1016\/j.bneo.2026.100237_bib25","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.2217\/fon-2018-0317","article-title":"Using response evaluation criteria in solid tumors in real-world evidence cancer research","volume":"14","author":"Feinberg","year":"2018","journal-title":"Future Oncol"},{"issue":"17","key":"10.1016\/j.bneo.2026.100237_bib26","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2217\/fon-2021-1229","article-title":"Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma","volume":"18","author":"Vo","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.bneo.2026.100237_bib27","series-title":"Validity of Surrogate Endpoints in Oncology: Executive Summary of Rapid Report A10-05, Version 1.1","year":"2011"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100237_bib28","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2023-182188","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2026.100237_bib29","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100237_bib30","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1182\/blood-2021-150751","article-title":"Addressing a new challenge in chronic lymphocytic leukemia: outcomes of therapies after exposure to both a covalent Bruton\u2019s tyrosine kinase inhibitor and venetoclax","volume":"138","author":"Thompson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100237_bib31","article-title":"Comparison of population characteristics in real-world clinical oncology Databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.bneo.2026.100237_bib32","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s12325-021-01659-0","article-title":"Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced NSCLC","volume":"38","author":"Ma","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100237_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100237_bib34","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): updated follow-up of transcend CLL 004","volume":"144","author":"Siddiqi","year":"2024","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:18:17Z","timestamp":1790687897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000488"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100237","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100237"}}